Skip to main content
OMDAOmada Health, Inc.Hold6.2·$19.18
HoldModerate Confidence
Investment thesis

Omada Health is growing revenue rapidly with a perfect 4-quarter earnings beat streak, but the stock is technically overbought, has already exceeded its price target, and notable insider selling adds a cautionary signal.

Thesis pillars

  • Strong Revenue Growth→Stable
  • Overbought Late Cycle Risk↓Deteriorating
  • Notable Insider Selling→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 6, 2026

Full reasoning →

Open full analysis

Omada Health, Inc. (OMDA) Stock Analysis

Range Bound setup

HoldVALUE-TRAP 2/5GrowthModerate Confidence

Healthcare · Health Information Services

Earnings in 7 days (2026-11-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $19.18, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Elevated risk factors.

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal... Read more

$19.18+27.8% A.UpsideScore 6.2/10#3 of 22 Health Information Services
QualityF-score8 / 9FCF yield1.01%
Stop $17.84Analyst target $24.51(−13% haircut)A.R:R 2.5:1
Analyst consensus$28.17+46.9%12 analysts
$24.51Analyst target
$19.18price
$28.17mean
$35

Hold if already holding. Not a fresh buy at $19.18, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Elevated risk factors. Chart setup: RSI 41 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.

Passes 5/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-29
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 20267d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Strong growth profile
Risks
Earnings in 7 days (event risk)
Elevated risk factors
Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (23 sells, 0.27% of cap)

Key Metrics

P/E (TTM)79.9
P/E (Fwd)34.5
Mkt Cap$1.2B
EV/EBITDA175.4
Profit Mgn1.4%
ROE1.8%
Rev Growth43.1%
Beta—
DividendNone
Rating analysts18

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.25bearish
IV84%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerlimited number of customers and channel partners
    10-K Item 1A: 'A substantial portion of our sales comes from or through a limited number of customers and channel partners that operate as resellers.'
  • MEDIUMSupplierlimited number of third-party suppliers
    10-K Item 1A: 'We depend on a limited number of third-party suppliers for certain devices and other supplies that we deliver to members in connection with our programs'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Volatile — 5.6% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Implied Vol
0.0
Short Interest
3.1
Days To Cover
4.9
Put Call
5.0
High IV: 84%Concentration risks: 2 MED (10-K Item 1A)
GatesEARNINGS PROXIMITY 7d<=7dMomentum 4.7<5.5 (soft — BUY_NOW allowed but watch)INSIDER 0.27%=MODERATEMomentum 4.7>=4.5A.R:R 2.5 ≥ 1.5No SEC red flagsSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
41 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $17.48Resistance $22.00

Price Targets

$18
$25
A.Upside+27.8%
A.R:R2.5:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeRisk-Off

Risk Alerts

! EARNINGS_PROXIMITY:7d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-11-05 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OMDA stock a buy right now?

Hold if already holding. Not a fresh buy at $19.18, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Elevated risk factors. Chart setup: RSI 41 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Analyst target $24.51 (+27.8%), stop $17.84 (−7.5%), A.R:R 2.5:1. Score 6.2/10, moderate confidence.

What is the OMDA stock price target?

Analyst target: $24.51 (+27.8% upside). Analyst target $24.51 (+27.8%), stop $17.84 (−7.5%), A.R:R 2.5:1. Stop-loss: $17.84.

What are the risks of investing in OMDA?

Earnings in 7 days (event risk); Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (23 sells, 0.27% of cap).

Is OMDA overvalued or undervalued?

Omada Health, Inc. trades at a P/E of 79.9 (forward 34.5). TrendMatrix value score: 6.2/10. Verdict: Hold.

What do analysts say about OMDA?

18 analysts cover OMDA with a consensus score of 4.0/5. Average price target: $28.

What does Omada Health, Inc. do?Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the...

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

Related stocks: HNGE (Hinge Health, Inc.) · HQY (HealthEquity, Inc.) · PRVA (Privia Health Group, Inc.) · CTEV (Claritev Corporation) · NRC (NRC Health)
Home › Stocks › OMDA

Latest news

Latest News

MarketBeat71d ago
MarketBeat71d ago
MarketBeat78d ago
MarketBeat78d ago
Investing.com78d ago
MarketBeat78d ago
Seeking Alpha78d agoEarnings
MarketBeat78d agoAnalyst
MarketBeat72d ago
MarketBeat79d ago
Investing.com India79d agoAnalyst
The Globe and Mail77d agoAnalyst
Yahoo Finance81d ago
MarketBeat75d ago
MarketBeat82d agoAnalyst
Sahm82d agoEarnings
Kalkine73d ago
Vinanet73d ago
Vinanet73d ago
MarketBeat76d ago
Loading more...